If you’ve heard about Zepbound® (tirzepatide) and are wondering whether Medicare will help pay for it in 2026, you’re not alone. Millions of older Americans struggle with obesity and its complications, including heart disease, sleep apnea, arthritis, high...
If you’ve heard about Medicare’s new GLP-1 Bridge Program, you may be wondering: “Will Medicare pay for Wegovy® in 2026?” The short answer is yes—but it depends on why you’re taking Wegovy and whether you meet the program’s...
Over the past several years, GLP-1 medications have transformed the treatment of obesity and Type 2 diabetes. While many people recognize these medications for their ability to promote significant weight loss, researchers have discovered that their benefits extend far...
The short answer is generally no. If you already receive coverage for a GLP-1 medication such as Ozempic® through your Medicare Part D prescription drug plan for Type 2 diabetes, you generally cannot switch to the Medicare GLP-1 Bridge Program. The Bridge Program was...
A Review of the Science Behind Medicare’s New Approach to Obesity Treatment and Cardiovascular Disease Prevention Beginning in July 2026, the Centers for Medicare & Medicaid Services (CMS) launched the Medicare GLP-1 Bridge Program, a temporary demonstration...
Published by DPC Medical-Dodson Pain Consultants, PA For millions of Americans, managing obesity and weight-related health conditions has been challenging—not only because of the complexity of weight loss itself, but also because of the cost of newer prescription...
